Scancell shares jump on new antibody agreement with major biotech firm

12th Jun 2024 07:53

(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".

The deal will see the unnamed company exclusively evaluate a Scancell investigational anti-glycan monoclonal antibody for development of novel therapeutic products.

Scancell has granted he company seven months exclusivity for evaluation, which includes an $1m exclusivity payment. The agreement also includes the option to licence.

"This is now the second anti-glycan monoclonal antibody generated via our proprietary GlyMab® platform to be evaluated, the first now being developed under a commercial licence agreement," said chief executive Lindy Durrant.

"This provides further validation of the potential of our antibody platform to create novel, differentiated antibody products."

The anti-glycan monoclonal antibody is one of five monoclonal antibodies currently in Scancell's antibody portfolio.

The stock was up 9.5% at 10.3p by 0824 BST.

Top Risers

Share	Price	Change
Armadale Capital (ACP)	0.10	0%
Petrel Resources (PET)	0.90	0%
Hornby (HRN)	21.50	0%
Helium One (HE1)	1.01	0%
Microsalt (SALT)	82.50	0%

Top Fallers

Share	Price	Change
Hummingbird Resources (HUM)	2.15	0%
Wood Group (J) (WG.)	49.84	0%
Fadel Partners (FADL)	60.00	0%
Electric Guitar (ELEG)	0.425	0%
Aferian (AFRN)	4.75	0%

Top By Volume

Share	Price	Volume
Nativo Resources (NTVO)	0.0025	0
Tower Resources (TRP)	0.029	0
Mosman Oil Gas (MSMN)	0.0375	0
Helium One (HE1)	1.01	0
Cap-xx (CPX)	0.135	0

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.